A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Clinical trial NCT05791201 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05791201
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-16
- Primary completion
- 2027-03-12
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.